Core Viewpoint - Aolide (688378) plans to invest in the construction of an OLED display core material PSPI material production base project to accelerate the domestic substitution process of key OLED materials [1][2] Group 1: Investment and Project Details - The company intends to raise approximately 300 million yuan through a private placement to fund the PSPI material production base project and supplement working capital [1] - The total investment for the PSPI material production base project is 240 million yuan, with an expected construction period of three years [1] - The project aims to alleviate current site constraints, enhance production capacity, and improve production efficiency for PSPI products [1][3] Group 2: Market Demand and Growth Potential - PSPI, or photosensitive polyimide, is a critical material in the manufacturing process of OLED displays, and its demand is expected to increase due to the expansion of the OLED downstream application market and the construction of domestic 8.6-generation OLED large-size panel production lines [1][2] - According to QYResearch, the global PSPI market size is projected to grow from 677 million USD in 2024 to 3.181 billion USD by 2031, with a compound annual growth rate (CAGR) of 25.1% [1] Group 3: Competitive Landscape and Company Position - Currently, foreign companies such as Toray, Fujifilm, Asahi Kasei, and HDM dominate the global PSPI material market, leading to challenges such as long procurement cycles and high prices for imported materials [2] - Aolide has achieved a comprehensive layout of OLED terminal light-emitting materials and has focused on high-performance PSPI materials as a key research and development project [2] - The company has successfully completed the entire development process for PSPI materials, achieving mass production and validation with major panel manufacturers [2] Group 4: Financial Projections and Business Synergy - The project is expected to generate approximately 382.5 million yuan in revenue and 57.51 million yuan in net profit in its first year of production [3] - Aolide anticipates that the project will significantly enhance its PSPI material mass production capacity and market supply capability, reducing reliance on imports and mitigating supply chain disruption risks [3]

Group 1: Storage Market Dynamics - The storage spot market is experiencing strong demand, leading to continued price increases for finished products, despite high prices [1] - Customers with low inventory levels are gradually accepting new pricing agreements, providing manufacturers with confidence to raise prices [1] - The significant price increases are affecting retail markets, with online and offline retailers raising prices for memory modules and SSDs, potentially reducing consumer purchasing willingness [1] Group 2: DRAM Industry Forecast - According to TrendForce, the DRAM industry revenue is expected to grow by 30.9% quarter-on-quarter in Q3 2025, reaching $41.4 billion due to rising contract prices and increased shipment volumes [1] - The fourth quarter is anticipated to see a significant increase in contract prices, with conventional DRAM prices expected to rise by 45%-50% [1] - The overall contract prices for conventional DRAM and HBM combined are projected to increase by 50%-55% [1] Group 3: Medical Device Market Growth - The Chinese medical device market is projected to reach ¥1.22 trillion by 2025, with over 33,000 production enterprises expected by the end of 2024, marking a 27.8% increase from the end of the 13th Five-Year Plan [2] - The industry is transitioning from "catching up" to "running alongside and leading," supporting the "Healthy China" strategy [2] Group 4: Flu Season Impact on Pharmaceuticals - The flu season has started early in China, with a 237% increase in sales of Oseltamivir over the past week, and a 180% increase for Maviral [2] - The peak of the flu season is expected between mid-December and early January [2] Group 5: Cinema Industry Growth - As of October 2023, China has added 233 cinemas and 1,588 screens, totaling 15,438 operating cinemas and 92,556 screens nationwide [3] - County-level cinemas account for 21.06% of the total, while town cinemas make up 18.01% [3] Group 6: Innovations in Medical Technology - Novo Nordisk's Kyinsu, the world's first weekly insulin and GLP-1 receptor agonist combination, has been approved in the EU for adults with type 2 diabetes [3] - This innovation represents a significant advancement in diabetes treatment options [3] Group 7: Corporate Developments - Allianz Partners plans to lay off 1,500 to 1,800 employees over the next 12-18 months, primarily in call center roles due to automation [5] - Novartis announced plans to cut up to 550 jobs in Switzerland by the end of 2027 as part of production adjustments [5]

Core Viewpoint - Aolide (688378.SH) plans to raise funds through a simplified procedure for a specific audience, with a total fundraising amount not exceeding 299.71 million yuan, which is capped at 30 million yuan and 20% of the net assets at the end of the previous year [1] Fundraising Details - The funds raised will be allocated to the OLED display core material PSPI material production base project and to supplement working capital [1]

Group 1 - The company, Aolide, announced a stock issuance plan authorized by the 2024 annual shareholders' meeting, aiming to raise up to approximately 300 million yuan [1] - The stock issuance will target no more than 35 specific investors, with the issuance price set at no less than 80% of the average trading price over the previous 20 trading days [1] - The raised funds will be allocated to two main projects: the OLED display core material PSPI production base project with a total investment of about 240 million yuan, and a working capital project with an investment of 60 million yuan [1] Group 2 - As of the latest report, Aolide's market capitalization stands at 6.1 billion yuan [2] - For the year 2024, Aolide's revenue composition is as follows: 68.15% from the chemical raw materials and chemical products manufacturing industry (C26), 31.76% from the specialized equipment manufacturing industry (C35), and 0.1% from other businesses [1]

Group 1 - Aolide plans to raise no more than 300 million yuan through a simplified procedure for issuing shares to specific targets, with net proceeds allocated to the production base project for OLED display core materials and to supplement working capital [1] - Wanbang's subsidiary has obtained a 10-year exclusive agency for sildenafil oral suspension, which is suitable for patients with swallowing difficulties [2] - Titan Technology and its affiliate plan to jointly invest in increasing capital for its subsidiary, Micro Detection, raising its registered capital from 10 million yuan to 50 million yuan [3] Group 2 - Jindike will not issue new batches of quadrivalent influenza virus split vaccine this year, having produced approximately 1.56 million doses [4] - Aladdin intends to purchase 35% equity of Youke for 61.25 million yuan, funded by its own or raised capital [5] - Gujia Home's application for a private placement of A-shares has been approved by the Shanghai Stock Exchange [7] Group 3 - Honghe Technology's application for a private placement of A-shares has been approved by the China Securities Regulatory Commission [9] - Guangdian Yuntong has won contracts totaling 308 million yuan for the construction of an artificial intelligence application pilot base [10] - Shanghai Mechanical plans to repurchase B-shares worth no more than 278 million yuan [11] Group 4 - Weiling Co. is planning a change of control, with shares representing 7.76% of the total being transferred [14] - Jiugang Hongxing intends to invest 200 million yuan to establish a wholly-owned subsidiary focusing on high-quality special steel materials [16] - Zhongjian Technology has submitted an application for H-share listing [17] Group 5 - Sainuo Medical has received registration approval for its coronary product in Pakistan [18] - Huafeng Aluminum plans to acquire 100% equity of Huafeng Puen for 100 million yuan [20] - Fuda Co. intends to establish a wholly-owned subsidiary with an investment of 30 million yuan [22] Group 6 - Su Yan Jingshen's application for a private placement of shares has been approved by the Shanghai Stock Exchange [24] - Zhongchuang Co. has set the inquiry transfer price at 25.75 yuan per share [25] - Jinpu Garden has had a lawsuit involving 26.557 million yuan accepted by the court [29] Group 7 - ICBC has approved the appointment of Zhao Guid as vice president [30] - Betta Pharmaceuticals has had its drug registration application for ensartinib accepted [32] - Times New Materials plans to invest 6 million euros to establish a wholly-owned subsidiary in Serbia [34] Group 8 - China State Construction has appointed Chen Yong as vice president [36] - Dayang Electric plans to invest 10 million yuan to establish an industrial fund [38] - Advanced Digital has appointed Liu Zhigang as deputy general manager [39] Group 9 - Tianqi Co. plans to transfer 7% equity of Youqi Intelligent for 130 million yuan [40] - Xinguo has submitted an application for H-share issuance and listing [42] - Jinhongshun's shareholder has terminated a share reduction plan [43] Group 10 - Wanrun Co.'s actual controller plans to increase shareholding between 365 million yuan and 730 million yuan [44] - Suzhou High-tech plans to sell 47% equity of its medical device subsidiary for 604 million yuan [45] - Huayou Cobalt's subsidiary has signed a product supply agreement with Yiwei Lithium Energy for approximately 127,800 tons of materials [47] Group 11 - China Communications has won 10 important projects totaling approximately 2.539 billion yuan [49] - Nopushin plans to raise no more than 1.45 billion yuan through a private placement [50] - Yun Aluminum plans to acquire minority stakes in three subsidiaries for a total of 2.267 billion yuan [51] Group 12 - Xiamen Tungsten plans to establish a 500 million yuan merger fund with multiple parties [52] - Aotewei has signed a contract worth approximately 700 million yuan [54] - Hemai Co.'s shareholders plan to reduce their holdings by no more than 3% [56]

Core Viewpoint - Aolide (688378.SH) plans to issue shares through a simplified procedure to raise a total of no more than 300 million yuan, which will be used for the production base project of OLED display core material PSPI and to supplement working capital [1] Group 1 - The company intends to raise funds through a specific target share issuance [1] - The total amount to be raised is capped at 300 million yuan, including the principal [1] - The net proceeds will be allocated to the PSPI material production base project and to enhance liquidity [1]

Core Points - The company, Aolide (688378.SH), announced plans to issue shares through a simplified procedure to specific investors, aiming to raise a total of no more than 300 million yuan, including the principal amount [1] - The net proceeds from this fundraising will be allocated to the production base project for OLED display core materials, specifically PSPI materials, and to supplement working capital [1]

Core Viewpoint - The company, Aolide, announced plans to issue shares to specific investors, aiming to raise no more than 300 million yuan for the production base project of OLED display core material PSPI and to supplement working capital [2] Group 1 - The total amount to be raised through the share issuance is capped at 300 million yuan [2] - The funds will be allocated to the production base project for OLED display core materials [2] - Additional funds will be used to enhance the company's working capital [2]

（吉林省长春市高新开发区硅谷新城生产力大厦 A 座 19 层） 2025 年度以简易程序向特定对象发行 股票方案论证分析报告 二〇二五年十一月 证券简称：奥来德 证券代码：688378 吉林奥来德光电材料股份有限公司 Jilin OLED Material Tech Co.，Ltd. 吉林奥来德光电材料股份有限公司（以下简称"奥来德"或"公司"）是上 海证券交易所科创板上市公司。为满足公司业务发展需求，增加公司资本实力， 提升盈利能力，根据《中华人民共和国公司法》（以下简称"《公司法》"）《中华 人民共和国证券法》（以下简称"《证券法》"）《上市公司证券发行注册管理办法》 （以下简称"《注册管理办法》"）《上海证券交易所上市公司证券发行上市审核规 则》（以下简称"《上市审核规则》"）等有关法律法规、规范性文件和《公司章程》 的规定，公司编制了以简易程序向特定对象发行股票方案的论证分析报告。 本论证分析报告中如无特别说明，相关用语具有与《吉林奥来德光电材料股 份有限公司 2025 年度以简易程序向特定对象发行股票预案》中相同的含义。 一、本次发行的背景和目的 1 类项目；2023 年 12 月，工业和信息化部出 ...

证券简称：奥来德 证券代码：688378 吉林奥来德光电材料股份有限公司 2025年度以简易程序向特定对象发行股票预案 公司声明 1、公司及董事会全体成员保证本预案内容真实、准确、完整，并确认不存 在虚假记载、误导性陈述或重大遗漏。 吉林奥来德光电材料股份有限公司 Jilin OLED Material Tech Co.，Ltd. （吉林省长春市高新开发区硅谷新城生产力大厦 A 座 19 层） 2025 年度以简易程序向特定对象 发行股票预案 二〇二五年十一月 2、本预案按照《上市公司证券发行注册管理办法》等法规及规范性文件的 要求编制。 3、本次以简易程序向特定对象发行股票完成后，公司经营与收益的变化由 公司自行负责；因本次以简易程序向特定对象发行股票引致的投资风险，由投资 者自行负责。 4、本预案是公司董事会对本次以简易程序向特定对象发行股票的说明，任 何与之相反的声明均属不实陈述。 5、投资者如有任何疑问，应咨询自己的股票经纪人、律师、专业会计师或 其他专业顾问。 6、本预案所述事项并不代表审批机关对于本次以简易程序向特定对象发行 股票相关事项的实质性判断、确认、批准或核准，本预案所述以简易程序向特定 ...